Heart drug shows promise in shrinking aggressive prostate tumors before surgery
NCT ID NCT07311915
First seen Jan 11, 2026 · Last updated May 02, 2026 · Updated 12 times
Summary
This study tests whether adding the heart medication propranolol to standard hormone therapy before surgery can improve outcomes for men with high-risk prostate cancer. About 30 participants will receive the combination treatment before their prostate removal. The goal is to see if this approach can eliminate or greatly reduce cancer in the removed prostate tissue.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Zhongda Hospital
Nanjing, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.